Honeywell Aerospace Inc. Common Stock vs uniQure N.V. Ordinary Shares — how do they compare? Honeywell Aerospace Inc. Common Stock trades at $156.54 (market cap $50.14B), while uniQure N.V. Ordinary Shares trades at $20.78 (market cap $1.48B). The key difference: Honeywell Aerospace Inc. Common Stock is far larger — about 33.9× uniQure N.V. Ordinary Shares's market cap, and uniQure N.V. Ordinary Shares is trading nearer its 52-week high, Honeywell Aerospace Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Honeywell Aerospace Inc. Common Stock for 0 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| HONA | QURE | |
|---|---|---|
Market Cap | $50.14B | $1.48B |
Volume | 1,433,364 | 2,488,780 |
Sector | Industrials | Health |
52-Week High | $269.95 | $70.59 |
52-Week Low | $151.58 | $9.03 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $64.96B | $728.62M |
Signals from Pluang's Aura AI — not financial advice
HONA trades at $158.18, up 0.58% today, with neutral technical indicators showing support at $156 and resistance at $160. The company reported Q2 2026 EPS of $1.87, missing expectations of $2.07, while revenue grew to $17.40B in 2025. Analyst consensus remains mixed with a $211.25 price target, but multiple class action lawsuits filed in October 2026 create significant legal overhang.
HONA faces near-term headwinds from earnings miss and legal challenges, though strong cash flow generation and analyst price targets suggest long-term potential. Investors should weigh the 42.9% buy rating against litigation risks and declining profit margins projected for 2026.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Honeywell Aerospace Inc. is an aerospace and defense technology company, spun off from Honeywell in June 2026, that designs and supplies avionics, propulsion components (including auxiliary power units and engines), and connectivity systems for commercial, defense, and space aircraft.
Read more on HONA →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →